Title: Efficacy and Safety of Mirikizumab for Ulcerative Colitis: A Systematic Review and
Meta-analysis of Randomized Controlled
Version: 2 Date: 07 Nov 2024
Reviewer's report:
This article aimed to identify the efficacy of Mirikizumab for UC. I appreciate the research
area that the authors have chosen to focus on. However, there are significant issues with meta-
analysis. I have specific comments on this matter that I believe will enhance this article.
Major Comments
1) The manuscript includes an excessive number of figures, which detracts from highlighting
the most significant results. Reducing the number of figures would improve focus and clarity
around the key findings.
2) Some figures are not referenced within the main text, making their purpose and the data
they represent unclear. Each figure should be explicitly cited to enhance coherence and
comprehension.
3) The methods section indicates that “If I² exceeded 50%, a random effects model was used;
if not, a fixed effects model was utilized.” However, the models applied in the figures do not
consistently reflect this approach. Ensuring consistency between the stated methodology and the
figures would strengthen the manuscript. This inconsistency can be observed, for example, in
Figure 9, where a fixed effects model is used despite I² being 51%.
4) Inclusion of a funnel plot is recommended to assess potential publication bias.
5) The analysis is based on only four studies, with D'Heans 2023 contributing dominantly to the
results. Given the limited number of studies and the disproportionate influence of a single study,
the justification for conducting a meta-analysis in this context is questionable
Minor Comments
1# Please spell out terms upon their first appearance in the manuscript. For example, "TB,"
"PRISMA," and "PICOS" should be spelled out initially to ensure clarity.
2# While I assume "I2" refers to "I²," spelling errors like this should be corrected for accuracy
and professionalism.
3# There are typographical errors in the manuscript, such as “Mirkuzemab.” Identifying and
correcting such spelling errors is important to maintain clarity and uphold the credibility of the
paper.
Title: Efficacy and Safety of Mirikizumab for Ulcerative Colitis: A Systematic Review and
Meta-analysis of Randomized Controlled
Version: 2 Date: 07 Nov 2024
Reviewer's report:
This article aimed to identify the efficacy of Mirikizumab for UC. I appreciate the research
area that the authors have chosen to focus on. However, there are significant issues with meta-
analysis. I have specific comments on this matter that I believe will enhance this article.
Major Comments
1) The manuscript includes an excessive number of figures, which detracts from highlighting
the most significant results. Reducing the number of figures would improve focus and clarity
around the key findings.
2) Some figures are not referenced within the main text, making their purpose and the data
they represent unclear. Each figure should be explicitly cited to enhance coherence and
comprehension.
3) The methods section indicates that “If I² exceeded 50%, a random effects model was used;
if not, a fixed effects model was utilized.” However, the models applied in the figures do not
consistently reflect this approach. Ensuring consistency between the stated methodology and the
figures would strengthen the manuscript. This inconsistency can be observed, for example, in
Figure 9, where a fixed effects model is used despite I² being 51%.
4) Inclusion of a funnel plot is recommended to assess potential publication bias.
5) The analysis is based on only four studies, with D'Heans 2023 contributing dominantly to the
results. Given the limited number of studies and the disproportionate influence of a single study,
the justification for conducting a meta-analysis in this context is questionable
Minor Comments
1# Please spell out terms upon their first appearance in the manuscript. For example, "TB,"
"PRISMA," and "PICOS" should be spelled out initially to ensure clarity.
2# While I assume "I2" refers to "I²," spelling errors like this should be corrected for accuracy
and professionalism.
3# There are typographical errors in the manuscript, such as “Mirkuzemab.” Identifying and
correcting such spelling errors is important to maintain clarity and uphold the credibility of the
paper.
Please review this paper.
user
Title: Efficacy and Safety of Mirikizumab for Ulcerative Colitis: A Systematic Review and
Meta-analysis of Randomized Controlled
Version: 2 Date: 07 Nov 2024
Reviewer's report:
This article aimed to identify the efficacy of Mirikizumab for UC. I appreciate the research
area that the authors have chosen to focus on. However, there are significant issues with meta-
analysis. I have specific comments on this matter that I believe will enhance this article.
Major Comments
1) The manuscript includes an excessive number of figures, which detracts from highlighting
the most significant results. Reducing the number of figures would improve focus and clarity
around the key findings.
2) Some figures are not referenced within the main text, making their purpose and the data
they represent unclear. Each figure should be explicitly cited to enhance coherence and
comprehension.
3) The methods section indicates that “If I² exceeded 50%, a random effects model was used;
if not, a fixed effects model was utilized.” However, the models applied in the figures do not
consistently reflect this approach. Ensuring consistency between the stated methodology and the
figures would strengthen the manuscript. This inconsistency can be observed, for example, in
Figure 9, where a fixed effects model is used despite I² being 51%.
4) Inclusion of a funnel plot is recommended to assess potential publication bias.
5) The analysis is based on only four studies, with D'Heans 2023 contributing dominantly to the
results. Given the limited number of studies and the disproportionate influence of a single study,
the justification for conducting a meta-analysis in this context is questionable
Minor Comments
1# Please spell out terms upon their first appearance in the manuscript. For example, "TB,"
"PRISMA," and "PICOS" should be spelled out initially to ensure clarity.
2# While I assume "I2" refers to "I²," spelling errors like this should be corrected for accuracy
and professionalism.
3# There are typographical errors in the manuscript, such as “Mirkuzemab.” Identifying and
correcting such spelling errors is important to maintain clarity and uphold the credibility of the
paper.
assistant